BIOIBÉRICA
9.3.2017 11:38:25 CET | Business Wire | Press release
“Everybody has heard of penicillin, but nobody knows what heparin is. And the fact is that heparin has saved as many lives as penicillin in the course of the 20 th century ”, explains Prof. Coen Hemker , a biochemist and Emeritus of the University of Maastricht, at the start of the documentary “Heparin: 100 years saving lives” . This 30-minute audiovisual recording has been directed by Carles Canet and produced by Broadcaster , with promotion from Bioibérica , to describe – on the basis of personal experiences – this anticoagulant drug which is so important in modern Medicine, having been declared a first-need drug by the World Health Organization.
In effect, this is the first documentary dedicated to this drug, and has been able to join the leading specialists and investigators in Hematology, Cardiology and Surgery, among other fields, as well as the drug industry, within one same audiovisual recording. Professionals from Spain (Hospital de la Santa Creu i Sant Pau , Hospital Universitari General de Catalunya , Hospital Germans Trias i Pujol , Banc de Sang i Teixits , Instituto Valenciano de Fertilidad , ISGlobal , IBEC ), the United States (Baylor University , Rensselaer Polytechnic Institute ), The Netherlands (Universidad de Maastricht , Synapse Research Institute ) and Italy (Instituto Ronzoni ), as well as international companies such as Sanofi , Laboratorios Rovi , BBraun or Bioibérica , have participated in the initiative
But the true central characters of this documentary are the patients who explain their own experiences: “I found it impossible to finish a training session and couldn’t believe that I would have to abandon water polo because of a clot in the subclavian vein at 17 years of age. Thanks to heparin, I was able to recover after six months, and everything that came afterwards was very much worthwhile”, explains Jennifer Pareja , a Spanish water polo player nominated the best player in the world in 2013.
The documentary can be seen online on Bioiberica website and is open to all those entities, educational institutions, organizations and people who wish to use and diffuse the recording. “Five out of every 10 people will need heparin at some point in life. Medicine wouldn’t be where it is today without it ”, explains Professor James Marcum , a historian at Baylor University in the United States.
Heparin , discovered in 1916, is a highly sulfated glycosaminoglycan – a natural substance composed of various molecules that inhibits blood clotting. Because of these properties, heparin is currently the most widely used drug for preventing and treating thrombosis. According to the International Society on Thrombosis and Hemostasis , one out of every four people in the world die of causes related to this disorder , which now produces more deaths each year than AIDS, breast cancer and traffic accidents combined.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170309005559/en/
Contact:
Bioibérica
Alba Soler i Conangla
+34 682 04 07
76 / +34 93 490 49 08
Communications Director
asoler@bioiberica.com
Visit
our press room
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
